Related Experiment Video
Updated: Sep 14, 2025

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
Published on: May 16, 2019
Pregnancy Outcomes in Epilepsy Patients Treated with Neuromodulating Devices
1Department of Neurology, Baylor College of Medicine, 7200 Cambridge Street, Suite 9A, Houston, TX, 77030, USA. lu.lin@bcm.edu.
Purpose Of Review:
Neuromodulation provides additional treatment options for patients with drug-resistant epilepsy who are not candidates or unwilling to undergo resective or ablative surgery. However, our current knowledge on the safety and efficacy of different neuromodulating devices during pregnancy is limited. This article reviews recent research on pregnancy outcomes in epilepsy patients treated with vagus nerve stimulation (VNS), deep brain stimulation (DBS), or responsive neurostimulation (RNS).
Recent Findings:
Currently available information about pregnancy outcomes in epilepsy patients with neuromodulating devices all comes from cases series or case reports. Randomized control trials or prospective observational studies are lacking in this patient population. The overall sample size is too small to draw conclusions on the safety of these neuromodulating devices in pregnancy and maternal outcomes including obstetric complications. There is no clear sign of device-related teratogenicity. Further research should be directed at establishing a pregnancy registry and conducting multi-center prospective studies to track pregnancy outcomes in epilepsy patients with various neuromodulating devices.
More Related Videos
08:23A Multimodal Imaging- and Stimulation-based Method of Evaluating Connectivity-related Brain Excitability in Patients with Epilepsy
Published on: November 13, 2016
04:51Pupillary Response as Assessment of Effective Seizure Induction by Electroconvulsive Therapy
Published on: April 11, 2019
Related Concept Videos
Epilepsy and Seizures: Overview
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
Antiepileptic Drugs: Glutamate Antagonists
Electroconvulsive Therapy